Similarly, the advent of HER2-targeted therapies for the treatment of women with newly diagnosed metastatic HER2-positive breast cancer has radically changed the outcome of what was until recently the most lethal form of breast cancer [169]. Here, ERBB2 is linked to breast cancer.